Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians.
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
LAROCCA, Alessandra;PALUMBO, AntonioLast
2016-01-01
Abstract
Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
[AUTHOR s VERSION] Musto - IMWG consensus statement for submission to Ann Oncol.pdf
Open Access dal 02/03/2018
Descrizione: Author's version. Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606. Erratum in: Ann Oncol. 2017 May 24;: PMID: 27864218. VC The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. The published version is available at: https://www.annalsofoncology.org/article/S0923-7534(19)32218-5/fulltext | https://doi.org/10.1093/annonc/mdw606 . When citing, please refer to the published version.
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
456.13 kB
Formato
Adobe PDF
|
456.13 kB | Adobe PDF | Visualizza/Apri |
|
[PUBLISHED Vsn.] Musto et al - 2016 - SPM IMWG - 1-s2.0-S0923753419322185-main.pdf
Accesso riservato
Descrizione: Published version. Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606. Erratum in: Ann Oncol. 2017 May 24;: PMID: 27864218. VC The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. The published version is available at: https://www.annalsofoncology.org/article/S0923-7534(19)32218-5/fulltext | https://doi.org/10.1093/annonc/mdw606 .
Tipo di file:
PDF EDITORIALE
Dimensione
234.07 kB
Formato
Adobe PDF
|
234.07 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
